Adaptimmune Therapeutics PLC
ADAP0.055USD
0.000
交易中 （美东）报价延迟15分钟
87.31M总市值
亏损市盈率 TTM
关于 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC 是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。其工程化 T 细胞受体 (TCR) 平台能够对 T 细胞进行工程化，以靶向和摧毁多种实体肿瘤类型的癌症。其细胞疗法候选药物包括 TCR T 细胞和 TruC T 细胞。其产品候选药物包括 afamitresgene autoleucel (afami-cel) 和 Lete-cel。afamicel 是一种细胞疗法，可为滑膜肉瘤患者提供治疗选择。该公司正在过渡 lete-cel，该疗法针对滑膜肉瘤和粘液样圆细胞脂肪肉瘤 (MRCLS) 患者的 NY-ESO 抗原。其临床管线包括 ADP-A2M4CD8 的 SURPASS-III II 期试验和 ADP-A2M4CD8 的 SURPASS I 期试验。该公司最先进的临床前项目是针对 PRAME 靶点 (ADP-600) 和 CD70 (ADP-520) 的 T 细胞疗法。ADAP-600 是一种工程化的 TCR T 细胞。
Adaptimmune Therapeutics PLC简介
公司代码ADAP
公司名称Adaptimmune Therapeutics PLC
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
员工数量506
证券类型Depository Receipt
年结日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编OX14 4RX
电话441235430000
网址https://www.adaptimmune.com/
公司代码ADAP
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
Adaptimmune Therapeutics PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 19 小时前
更新时间: 19 小时前
持股股东
股东类型
持股股东
持股股东
占比
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
8.52%
EcoR1 Capital, LLC
4.15%
MPM Capital Inc.
1.81%
MPM BioImpact LLC
1.66%
其他
74.89%
持股股东
持股股东
占比
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
8.52%
EcoR1 Capital, LLC
4.15%
MPM Capital Inc.
1.81%
MPM BioImpact LLC
1.66%
其他
74.89%
股东类型
持股股东
占比
Hedge Fund
19.14%
Investment Advisor/Hedge Fund
9.14%
Research Firm
2.08%
Investment Advisor
0.98%
Individual Investor
0.63%
Pension Fund
0.07%
Venture Capital
0.03%
其他
67.94%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
177
83.31M
31.43%
-88.42M
2025Q2
192
118.54M
44.72%
-45.84M
2025Q1
196
118.11M
44.76%
-44.66M
2024Q4
195
128.66M
50.28%
-22.55M
2024Q3
199
155.41M
60.76%
-9.79M
2024Q2
202
157.35M
61.56%
-15.41M
2024Q1
213
165.17M
64.85%
-7.14M
2023Q4
210
146.11M
64.44%
-17.89M
2023Q3
229
151.45M
66.86%
-8.97M
2023Q2
226
147.93M
65.80%
+13.35M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Long Focus Capital Management LLC
23.76M
8.96%
--
--
Jun 30, 2025
Two Seas Capital LP
22.58M
8.52%
+2.05M
+9.99%
Jun 30, 2025
EcoR1 Capital, LLC
11.00M
4.15%
-16.40M
-59.86%
Aug 15, 2025
MPM Capital Inc.
4.81M
1.81%
-526.04K
-9.86%
Jun 30, 2025
MPM BioImpact LLC
4.41M
1.66%
-482.52K
-9.86%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.22M
1.59%
+1.59M
+60.49%
Jun 30, 2025
Rock Springs Capital Management LP
2.48M
0.94%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.96M
0.74%
-254.07K
-11.45%
Jun 30, 2025
Renaissance Technologies LLC
1.88M
0.71%
+69.00K
+3.80%
Jun 30, 2025
BofA Global Research (US)
1.14M
0.43%
-5.30K
-0.46%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12 小时前
更新时间: 12 小时前
机构名称
占比
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
